Q-omics provides the consensus-scored LYNX1 profile across patient tissues and cancer cell-line models. LYNX1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LYNX1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LYNX1 RNA expression shows 15,618 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where LYNX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYNX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYNX1 survival associations across molecular data types. LYNX1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYNX1 RNA expression–survival associations across cancer types. High LYNX1 expression shows unfavorable associations in STAD, BRCA and GBM, but favorable associations in LUAD, KIRP and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LYNX1 RNA expression.
This table summarizes LYNX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LYNX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYNX1 shows lower tumor expression in KIRC, KIRP, COAD, BLCA and HNSC and higher tumor expression in LIHC. The KIRC box plot shows higher LYNX1 RNA expression in normal versus tumor tissue (log2 FC = −1.438, t-test p < 0.001).
This table shows molecular features associated with LYNX1 in patient tissues and cancer cell lines. In patient samples, LYNX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LYNX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and KIDNEY.
